Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel cancer immunotherapy products based on the chimeric antigen receptor engineered T (CAR T) cell technology. The company's CAR T product candidates include MB-101, a IL13Ra2 CAR T cell program which is in Phase I clinical study for glioblastoma; and MB-102, a CD123 CAR T cell program to treat acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm; and MB-106, a CD20 CAR T cell program that is in Phase I clinical study for the treatment of B cell non-Hodgkin lymphoma. It also develops MB-104, a CS1 CAR T, which is in Preclinical study for multiple myeloma and light chain amyloidosisy; MB-103, a human epidermal growth factor receptor 2 CAR T that is in Preclinical study to treat glioblastoma multiforme and metastatic breast cancer to brain; and MB-105, a prostate stem-cell antigen CAR T for prostate and pancreatic cancers. The company has a partnership agreement with the City of Hope National Medical Center and Fred Hutchinson Cancer Research Center to develop proprietary CAR T therapies across various cancers. It also holds a license agreement with Harvard University; and a research collaboration agreement with Beth Israel Deaconess Medical Center for the development of CRISPR/Cas9-enhanced CAR T therapies for the treatment of cancer. The company was incorporated in 2015 and is based in New York, New York. Mustang Bio, Inc. is a subsidiary of Fortress Biotech, Inc.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone781-652-4500
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees6
OptionableOptionable
Mustang Bio (NASDAQ:MBIO) Frequently Asked Questions
What is Mustang Bio's stock symbol?
Mustang Bio trades on the NASDAQ under the ticker symbol "MBIO."
How were Mustang Bio's earnings last quarter?
Mustang Bio Inc (NASDAQ:MBIO) released its quarterly earnings data on Tuesday, November, 13th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.20) by $0.08. View Mustang Bio's Earnings History.
When is Mustang Bio's next earnings date?
What price target have analysts set for MBIO?
1 analysts have issued 12-month price targets for Mustang Bio's shares. Their forecasts range from $18.00 to $18.00. On average, they anticipate Mustang Bio's share price to reach $18.00 in the next twelve months. This suggests a possible upside of 462.5% from the stock's current price. View Analyst Price Targets for Mustang Bio.
What is the consensus analysts' recommendation for Mustang Bio?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mustang Bio in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Mustang Bio.
Has Mustang Bio been receiving favorable news coverage?
News stories about MBIO stock have been trending very positive recently, according to InfoTrie Sentiment. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Mustang Bio earned a news impact score of 3.2 on InfoTrie's scale. They also gave headlines about the company a news buzz of 4.0 out of 10, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near term.
Who are some of Mustang Bio's key competitors?
Some companies that are related to Mustang Bio include Xeris Pharmaceuticals (XERS), Rigel Pharmaceuticals (RIGL), Abeona Therapeutics (ABEO), Keryx Biopharmaceuticals (KERX), Stemline Therapeutics (STML), Kindred Biosciences (KIN), Concert Pharmaceuticals (CNCE), Insys Therapeutics (INSY), ZIOPHARM Oncology (ZIOP), Evelo Biosciences (EVLO), BioDelivery Sciences International (BDSI), Achillion Pharmaceuticals (ACHN), Lannett (LCI), OptiNose (OPTN) and BIOFRONTERA AG/ADR (BFRA).
Who are Mustang Bio's key executives?
Mustang Bio's management team includes the folowing people:
- Mr. Michael S. Weiss, Exec. Chairman (Age 53)
- Dr. Manuel Litchman, Pres, CEO & Director (Age 65)
- Mr. David Jay Horin CPA, Interim Chief Financial Officer (Age 51)
- Mr. Brian K. Achenbach, VP of Fin. & Corp. Controller (Age 54)
- Dr. Knut Niss, Chief Technology Officer
Who are Mustang Bio's major shareholders?
Which institutional investors are buying Mustang Bio stock?
How do I buy shares of Mustang Bio?
Shares of MBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Mustang Bio's stock price today?
One share of MBIO stock can currently be purchased for approximately $3.20.
How big of a company is Mustang Bio?
Mustang Bio has a market capitalization of $90.24 million. The company earns $-31,280,000.00 in net income (profit) each year or ($0.75) on an earnings per share basis. Mustang Bio employs 6 workers across the globe.
What is Mustang Bio's official website?
How can I contact Mustang Bio?
Mustang Bio's mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The company can be reached via phone at 781-652-4500 or via email at [email protected]
MarketBeat Community Rating for Mustang Bio (NASDAQ MBIO)
MarketBeat's community ratings are surveys of what our community members think about Mustang Bio and other stocks. Vote "Outperform" if you believe MBIO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MBIO will underperform the S&P 500 over the long term. You may vote once every thirty days.
